Mutations in the gene glucosidase, beta acid 1 (GBA1) are the strongest genetic risk factor for Parkinson’s disease (PD) and are associated with faster disease progression. GBA1 is expressed in all cell types of the central nervous system, with some evidence supporting higher expression in glial cells than neurons. To elucidate possible specific functions in neurons versus glia, we differentiated human induced pluripotent stem cells (iPSCs) generated from an individual with PD heterozygous for the GBA1 pathogenic null variant IVS2+1 ( GBA1IVS/+ ), homozygous GBA1 IVS2+1 isogenic to G BA1IVS/+ ( GBA1IVS/IVS ) and a healthy unaffected age-and sex-matched individual ( GBA1+/+ ). GBA1 expression was reduced in GBA1IVS/+ and GBA1IVS/IVS neurons and astrocytes. Endolysosomal trafficking was significantly altered in G BA1- deficient neurons with enlarged early and recycling endosome and lysosome compartments in neurons but not in astrocytes. High molecular weight oligomerization of α-synuclein and phosphorylated Ser129 α-synuclein were present in GBA1IVS/+ and GBA1IVS/IVS neurons but not in GBA1+/+ neurons, or in GBA1- deficient or GBA1+/+ astrocytes. Transcriptomic analysis of GBA1 -deficient neurons and astrocytes revealed cell-type specific profiles. GBA1 deficiency in neurons downregulated immune response and upregulated cholesterol synthesis pathways, while GBA1 deficiency in astrocytes downregulated genes associated with translation and upregulated genes involved in extracellular matrix biogenesis. Transcriptomic analysis also suggests that GBA1 deficiency induces neurotoxic reactivity in astrocytes. Together, these findings indicate that GBA1 deficiency has cell type-specific effects, with increased neuronal vulnerability to endolysosomal trafficking leading to α-synucleinopathy while GBA1 deficiency in astrocytes leads to increased neurotoxic reactivity independent of endolysosomal trafficking and α-synucleinopathy. Highlights ### Competing Interest Statement The authors have declared no competing interest. * AD : Alzheimer’s disease CBE : conduritol B epoxide DEG : differentially expressed gene DLB : dementia with Lewy Bodies EEA1 : early endosome antigen 1 GBA1 : glucosidase, beta acid 1 iPSC : induced pluripotent stem cell LAMP1 : lysosome-associated membrane protein 1 MSA : multiple system atrophy NPC : neural progenitor cell PD : Parkinson’s disease National Institute of Neurological Disorders and Stroke, https://ror.org/01s5ya894, R01 NS119897-01, R21 NS118476-01A1 United States Department of Veterans Affairs, https://ror.org/05rsv9s98, I01CX001702 Parkinson's Foundation, https://ror.org/05mx85j86, PF-CRA-1891 John H. Tietze Foundation Trust, https://ror.org/01tv7v957, 2020 John H. Tietze Stem Cell Scientist Award

Protein production using Escherichia coli is a cornerstone of modern biotechnology. In this study, we developed a novel auto-expression medium to maximize protein production. Each E. coli strain tested was capable of auto-expression in response to galactose, including strains in which the endogenous lacZ had been disrupted. This provides key evidence that galactose can regulate the lac operon independent of known lac operon-regulated metabolism. The enhanced capabilities of the novel auto-expression medium were documented across protein production systems including (1) increased yields for routinely expressed proteins (e.g. eGFP), (2) improved expression of human cytochrome c within a dual expression system, (3) robust auto-expression in lacZ-deficient strains producing proteins with challenging disulfide bonds, and (4) reproducible 8-fold increase in SpCas9 yields, at ≥ 95% purity. This novel medium can streamline production and improve yields for routine as well as challenging proteins, accelerating recombinant protein production and creating new opportunities in biotechnology and structural biology.

Ion channels provide the basis for the nervous system’s intrinsic electrical activity. Neuronal excitability is a characteristic property of neurons and is critical for all functions of the nervous system. Glia cells fulfill essential supportive roles, but unlike neurons, they also retain the ability to divide. This can lead to uncontrolled growth and the formation of gliomas. Ion channels are involved in the unique biology of gliomas pertaining to peritumoral pathology and seizures, diffuse invasion, and treatment resistance. The emerging picture shows ion channels in the brain at the crossroads of neurophysiology and fundamental pathophysiological processes of specific cancer behaviors as reflected by uncontrolled proliferation, infiltration, resistance to apoptosis, metabolism, and angiogenesis. Ion channels are highly druggable, making them an enticing therapeutic target. Targeting ion channels in difficult-to-treat brain tumors such as gliomas requires an understanding of their extremely heterogenous tumor microenvironment and highly diverse molecular profiles, both representing major causes of recurrence and treatment resistance. In this review, we survey the current knowledge on ion channels with oncogenic behavior within the heterogeneous group of gliomas, review ion channel gene expression as genomic biomarkers for glioma prognosis and provide an update on therapeutic perspectives for repurposed and novel ion channel inhibitors and electrotherapy.

To investigate why GBA mutations are associated with faster progression of Parkinson's disease (PD).

To investigate if GBA has a neuroprotective role in astrocytes.

Many neurodegenerative diseases are characterized by abnormal protein aggregates, including the two most common neurodegenerative diseases Alzheimer's disease (AD) and Parkinson's disease (PD). In the global search to prevent and treat diseases, most research has been focused on the early stages of the diseases, including how these pathogenic protein aggregates are initially formed. We argue, however, that an equally important aspect of disease etiology is the characteristic spread of protein aggregates throughout the nervous system, a key process in disease progression. Growing evidence suggests that both alterations in lipid metabolism and dysregulation of extracellular vesicles (EVs) accelerate the spread of protein aggregation and progression of neurodegeneration, both in neurons and potentially in surrounding glia. We will review how these two pathways are intertwined and accelerate the progression of AD and PD. Understanding how lipid metabolism, EV biogenesis, and EV uptake regulate the spread of pathogenic protein aggregation could reveal novel therapeutic targets to slow or halt neurodegenerative disease progression.

Abnormal protein aggregation within neurons is a key pathologic feature of Parkinson's disease (PD). The spread of brain protein aggregates is associated with clinical disease progression, but how this occurs remains unclear. Mutations in glucosidase, beta acid 1 (GBA), which encodes glucocerebrosidase (GCase), are the most penetrant common genetic risk factor for PD and dementia with Lewy bodies and associate with faster disease progression. To explore how GBA mutations influence pathogenesis, we previously created a Drosophila model of GBA deficiency (Gba1b) that manifests neurodegeneration and accelerated protein aggregation. Proteomic analysis of Gba1b mutants revealed dysregulation of proteins involved in extracellular vesicle (EV) biology, and we found altered protein composition of EVs from Gba1b mutants. Accordingly, we hypothesized that GBA may influence pathogenic protein aggregate spread via EVs. We found that accumulation of ubiquitinated proteins and Ref(2)P, Drosophila homologue of mammalian p62, were reduced in muscle and brain tissue of Gba1b flies by ectopic expression of wildtype GCase in muscle. Neuronal GCase expression also rescued protein aggregation both cell-autonomously in brain and non-cell-autonomously in muscle. Muscle-specific GBA expression reduced the elevated levels of EV-intrinsic proteins and Ref(2)P found in EVs from Gba1b flies. Perturbing EV biogenesis through neutral sphingomyelinase (nSMase), an enzyme important for EV release and ceramide metabolism, enhanced protein aggregation when knocked down in muscle, but did not modify Gba1b mutant protein aggregation when knocked down in neurons. Lipidomic analysis of nSMase knockdown on ceramide and glucosylceramide levels suggested that Gba1b mutant protein aggregation may depend on relative depletion of specific ceramide species often enriched in EVs. Finally, we identified ectopically expressed GCase within isolated EVs. Together, our findings suggest that GCase deficiency promotes accelerated protein aggregate spread between cells and tissues via dysregulated EVs, and EV-mediated trafficking of GCase may partially account for the reduction in aggregate spread.